The MonumenTAL-3 randomized study evaluated a GPRC5D-directed bispecific T cell engager, talquetamab, administered in combination with either daratumumab or daratumumab–pomalidomide, versus a control regimen of daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma who had received at least one prior line of therapy. According to the accessible report, talquetamab-containing regimens conferred a statistically significant improvement in progression-free survival compared with the control arm.
These findings identify talquetamab-based combinations as a new therapeutic option for patients with early relapsed and/or refractory disease. The News & Views–style article highlights the potential clinical impact of adding a GPRC5D-targeted T cell engager to established anti-myeloma backbones, particularly in a setting where patients have limited options after early relapse or refractoriness to standard therapies.
The article does not present detailed numerical efficacy measures, duration of follow-up, patient subgroup data, or safety outcomes for MonumenTAL-3 in the accessible text. Those specifics were not reported in the source material provided here.
The authors emphasize the immediate practical question posed by the MonumenTAL-3 results: how should talquetamab-based regimens be positioned relative to, or combined with, existing or emerging BCMA-directed T cell–redirecting therapies? The myeloma therapeutic landscape already includes multiple modalities targeting BCMA, such as CAR T cells and bispecific T cell engagers, which have altered treatment algorithms for relapsed and refractory disease.
Because talquetamab targets GPRC5D rather than BCMA, it provides an alternative antigen target and therefore a potentially complementary or sequential option to BCMA‑directed approaches. However, the report notes that integration and sequencing strategies are unresolved: clinicians must decide whether to employ talquetamab combinations before or after BCMA-targeted therapies, whether cross-resistance or antigen escape affects sequencing choices, and how best to choose combination partners and patient populations for each approach.
The accessible text does not include comparative head‑to‑head data between talquetamab regimens and specific BCMA-directed therapies, nor does it report mechanistic or biomarker data that would directly inform sequencing decisions. Those data were not reported in the source.
To situate MonumenTAL-3 in the broader field, the article cites multiple recent and influential trials in relapsed and refractory multiple myeloma. Examples referenced include randomized and nonrandomized studies of BCMA-directed CAR T-cell products and bispecific antibodies, combinations such as teclistamab plus daratumumab, and reported experiences with GPRC5D-targeted CAR T cells. Additional cited work includes trials involving belantamab mafodotin combined with proteasome inhibitors or immunomodulatory drugs, and earlier talquetamab clinical studies assessing safety and activity.
By citing this set of reports, the authors underscore that MonumenTAL-3 builds on a rapidly evolving evidence base of T cell–redirecting immunotherapies and antibody–drug conjugates for relapsed and refractory myeloma. The article implies that these contemporary data collectively broaden options but complicate decision-making because direct comparisons across modalities are limited.
The authors identify several areas of clinical uncertainty that emerge from the MonumenTAL-3 findings:
Optimal sequencing: Should talquetamab combinations be used before BCMA-directed CAR T or bispecific therapy, or reserved for patients progressing after BCMA-directed approaches?
Patient selection: Which patients—based on prior therapies, timing of relapse, disease biology or comorbidities—are most likely to benefit from talquetamab-containing regimens?
Combination strategy: Which partner agents (for example, daratumumab with or without pomalidomide) offer the best efficacy and tolerability when combined with talquetamab, and how should toxicity management be approached?
Comparative effectiveness: How do talquetamab-based regimens compare directly with BCMA-directed therapies in clinically relevant outcomes such as response depth, durability, quality of life, and safety?
Mechanisms of resistance: What are the mechanisms driving resistance to T cell–redirecting therapies, including antigen loss or plasma cell identity changes, and how might these mechanisms influence therapy selection?
The source raises these questions as themes for future research and clinical discussion; detailed answers and data addressing each question were not provided in the accessible content.
The accessible article is a concise News & Views–type commentary and does not reproduce full trial data for MonumenTAL-3. As such, important details are not reported in the source text available here, including:
These gaps underscore the need to consult the full MonumenTAL-3 publication or primary trial reports for clinicians seeking actionable numerical data and safety information. The broader referenced literature provides additional context but does not resolve the comparative and sequencing questions raised.
In summary, the MonumenTAL-3 results reported in the accessible text introduce talquetamab-based combinations as a promising option for patients with early relapsed and/or refractory multiple myeloma, while also highlighting several unresolved clinical and research questions about how best to integrate these regimens with the expanding array of BCMA-directed and other immunotherapeutic approaches. The source does not report detailed trial numbers or safety data; those specifics should be obtained from the full trial publication.